PH12020550722A1 - Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye - Google Patents

Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Info

Publication number
PH12020550722A1
PH12020550722A1 PH12020550722A PH12020550722A PH12020550722A1 PH 12020550722 A1 PH12020550722 A1 PH 12020550722A1 PH 12020550722 A PH12020550722 A PH 12020550722A PH 12020550722 A PH12020550722 A PH 12020550722A PH 12020550722 A1 PH12020550722 A1 PH 12020550722A1
Authority
PH
Philippines
Prior art keywords
eye
posterior segment
acid
treating diseases
topical composition
Prior art date
Application number
PH12020550722A
Other languages
English (en)
Inventor
Nortes Xavier Capdevila
Aquilu Javier Sanagustin
Ga¥An Maria Isabel Delgado
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of PH12020550722A1 publication Critical patent/PH12020550722A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12020550722A 2017-12-04 2020-05-27 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye PH12020550722A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382832 2017-12-04
PCT/EP2018/082999 WO2019110416A1 (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Publications (1)

Publication Number Publication Date
PH12020550722A1 true PH12020550722A1 (en) 2021-02-15

Family

ID=60673756

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020550722A PH12020550722A1 (en) 2017-12-04 2020-05-27 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Country Status (24)

Country Link
US (1) US20200390729A1 (enExample)
EP (1) EP3720428B1 (enExample)
JP (1) JP2021505554A (enExample)
KR (1) KR102756155B1 (enExample)
CN (1) CN111542316A (enExample)
AU (1) AU2018378981B2 (enExample)
BR (1) BR112020011160A2 (enExample)
CA (1) CA3083835A1 (enExample)
CL (1) CL2020001426A1 (enExample)
DK (1) DK3720428T3 (enExample)
ES (1) ES2941036T3 (enExample)
FI (1) FI3720428T3 (enExample)
HR (1) HRP20230319T1 (enExample)
HU (1) HUE061852T2 (enExample)
MA (1) MA50991B1 (enExample)
MX (1) MX2020005809A (enExample)
MY (1) MY205498A (enExample)
PH (1) PH12020550722A1 (enExample)
PL (1) PL3720428T3 (enExample)
PT (1) PT3720428T (enExample)
SG (1) SG11202004940VA (enExample)
SI (1) SI3720428T1 (enExample)
WO (1) WO2019110416A1 (enExample)
ZA (1) ZA202003944B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300017430A1 (it) * 2023-08-22 2025-02-22 Service Biotech srl Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio
CN117257963B (zh) * 2023-11-02 2024-07-16 广州准优生物科技有限公司 含脐带间充质干细胞外泌体的眼用药剂及其制备方法和用途
CN117643573B (zh) * 2024-01-29 2024-05-03 天津医科大学眼科医院 一种可递送药物至眼后节的纳米滴眼液及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
BR112014013041A2 (pt) * 2011-11-30 2019-09-24 Xigen Inflammation Ltd uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco
PT2777699T (pt) * 2012-02-02 2017-07-07 Invesfovea S L Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade
EA201491643A1 (ru) * 2012-03-05 2015-02-27 Уэйн Стейт Юниверсити Идентификация мутаций канал-опсина-2 (chop2) и способы применения
CA2871528A1 (en) * 2012-04-24 2013-10-31 Thrombogenics N.V. Anti-pdgf-c antibodies
EP2875811A1 (en) * 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages

Also Published As

Publication number Publication date
WO2019110416A1 (en) 2019-06-13
MY205498A (en) 2024-10-23
AU2018378981A1 (en) 2020-07-16
KR102756155B1 (ko) 2025-01-20
DK3720428T3 (da) 2023-03-20
EP3720428B1 (en) 2023-01-11
MA50991A (fr) 2020-10-14
EP3720428A1 (en) 2020-10-14
BR112020011160A2 (pt) 2020-11-17
ZA202003944B (en) 2022-12-21
KR20200096569A (ko) 2020-08-12
HRP20230319T1 (hr) 2023-05-12
AU2018378981B2 (en) 2024-10-24
CN111542316A (zh) 2020-08-14
FI3720428T3 (fi) 2023-03-30
ES2941036T3 (es) 2023-05-16
SI3720428T1 (sl) 2023-05-31
US20200390729A1 (en) 2020-12-17
CA3083835A1 (en) 2019-06-13
PL3720428T3 (pl) 2023-05-08
MX2020005809A (es) 2020-08-20
JP2021505554A (ja) 2021-02-18
SG11202004940VA (en) 2020-06-29
MA50991B1 (fr) 2023-03-31
HUE061852T2 (hu) 2023-08-28
PT3720428T (pt) 2023-04-03
CL2020001426A1 (es) 2020-11-06

Similar Documents

Publication Publication Date Title
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2021002321A (es) Nuevos metodos.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
MX2019004549A (es) Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
EP4324454A3 (en) Cross-linking agents and associated methods
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
AU2017261303A1 (en) Ophthalmic compositions
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
PH12021550039A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MY199237A (en) Methods of treating ocular conditions
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2013184650A3 (en) Treatment of ocular inflammatory diseases using laquinimod
NZ713295A (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
AU2020299145A8 (en) Compositions and methods for treating eye diseases
MX387961B (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2022006523A (es) Composicion que comprende budesonida para uso oftalmico.
MX2017012999A (es) Acido pirrolidona carboxilico (pca) para uso oftalmico.